6.34
price down icon4.80%   -0.32
after-market 시간 외 거래: 6.40 0.06 +0.95%
loading
전일 마감가:
$6.66
열려 있는:
$6.67
하루 거래량:
11.32M
Relative Volume:
2.32
시가총액:
$1.65B
수익:
$6.28B
순이익/손실:
$700.00M
주가수익비율:
2.355
EPS:
2.6922
순현금흐름:
$537.00M
1주 성능:
-29.08%
1개월 성능:
-38.74%
6개월 성능:
-51.82%
1년 성능:
-64.48%
1일 변동 폭
Value
$6.32
$6.84
1주일 범위
Value
$6.32
$9.28
52주 변동 폭
Value
$6.32
$19.05

오가논 & Co Stock (OGN) Company Profile

Name
명칭
Organon Co
Name
전화
551-430-6000
Name
주소
30 HUDSON STREET, JERSEY CITY
Name
직원
10,000
Name
트위터
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
OGN's Discussions on Twitter

OGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
OGN
Organon Co
6.34 1.73B 6.28B 700.00M 537.00M 2.6922
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.53 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.60 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
225.14 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.80 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.58 217.38B 63.43B 16.42B 14.72B 6.4861

오가논 & Co Stock (OGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-10-27 다운그레이드 Piper Sandler Overweight → Underweight
2025-05-02 다운그레이드 Evercore ISI Outperform → In-line
2024-09-06 다운그레이드 JP Morgan Neutral → Underweight
2023-11-03 다운그레이드 Goldman Buy → Neutral
2023-09-21 개시 Barclays Overweight
2023-03-16 개시 Raymond James Outperform
2022-10-14 다운그레이드 BofA Securities Neutral → Underperform
2022-09-06 업그레이드 Piper Sandler Neutral → Overweight
2022-08-05 다운그레이드 BofA Securities Buy → Neutral
2022-04-27 개시 Goldman Buy
2022-04-06 재개 Morgan Stanley Equal-Weight
2021-10-07 개시 Piper Sandler Neutral
2021-09-01 개시 BofA Securities Buy
2021-07-22 개시 Citigroup Buy
2021-06-15 개시 JP Morgan Neutral
2021-06-11 개시 Morgan Stanley Equal-Weight
2021-06-10 개시 Evercore ISI Outperform
모두보기

오가논 & Co 주식(OGN)의 최신 뉴스

pulisher
Oct 29, 2025

MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.

Oct 29, 2025
pulisher
Oct 29, 2025

Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights

Oct 29, 2025
pulisher
Oct 29, 2025

Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st

Oct 29, 2025
pulisher
Oct 29, 2025

Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat

Oct 29, 2025
pulisher
Oct 28, 2025

Why Organon (OGN) Stock Is Down Today - TradingView

Oct 28, 2025
pulisher
Oct 28, 2025

Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade

Oct 28, 2025
pulisher
Oct 28, 2025

Organon hit hard over ousted CEO scandal - The Pharma Letter

Oct 28, 2025
pulisher
Oct 28, 2025

The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent

Oct 28, 2025
pulisher
Oct 28, 2025

Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛

Oct 28, 2025
pulisher
Oct 28, 2025

Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia

Oct 28, 2025
pulisher
Oct 28, 2025

Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ

Oct 28, 2025
pulisher
Oct 27, 2025

Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire

Oct 27, 2025
pulisher
Oct 27, 2025

Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma

Oct 27, 2025
pulisher
Oct 27, 2025

Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize

Oct 27, 2025
pulisher
Oct 27, 2025

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance

Oct 27, 2025
pulisher
Oct 27, 2025

Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC

Oct 27, 2025
pulisher
Oct 27, 2025

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's

Oct 27, 2025
pulisher
Oct 27, 2025

Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine

Oct 27, 2025
pulisher
Oct 27, 2025

Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg.com

Oct 27, 2025
pulisher
Oct 27, 2025

Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali to resign after probe into contraceptive sales - Reuters

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices - Stocktwits

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co. Announces CEO Changes - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon stock tumbles after CEO resigns amid sales practice investigation By Investing.com - Investing.com UK

Oct 27, 2025
pulisher
Oct 27, 2025

Organon falls as CEO resigns after probe into contraceptive sales - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Stock Titan

Oct 27, 2025
pulisher
Oct 27, 2025

Co. (7XP) stock considered safe havenMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Co. (7XP) stock in 20252025 Big Picture & Capital Efficiency Focused Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

Organon & Co. (NYSE:OGN) Given Sell (D+) Rating at Weiss Ratings - MarketBeat

Oct 26, 2025
pulisher
Oct 26, 2025

Co. (7XP) stock survive global slowdown2025 Sector Review & Safe Entry Point Alerts - newser.com

Oct 26, 2025
pulisher
Oct 24, 2025

Assessing Organon Stock After a 39.5% Drop and Recent Portfolio Moves - Yahoo Finance

Oct 24, 2025
pulisher
Oct 23, 2025

Organon (OGN) Laps the Stock Market: Here's Why - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

Organon (OGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025
pulisher
Oct 22, 2025

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com

Oct 22, 2025
pulisher
Oct 21, 2025

Organon & Co. (OGN) Stock Analysis: Exploring a 40.69% Potential Upside Amidst Healthcare Sector Challenges - DirectorsTalk Interviews

Oct 21, 2025

오가논 & Co (OGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general SNY
$50.68
price down icon 0.74%
drug_manufacturers_general PFE
$24.29
price down icon 0.86%
$118.50
price up icon 0.53%
$291.77
price down icon 0.11%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
자본화:     |  볼륨(24시간):